CuraScientific Corp.

As of September 30, 2023, CuraScientific Corp. carries a market capitalization of 3.42M, placing it among publicly traded companies globally. Its enterprise value stands at 4.11M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, CuraScientific Corp. has 2.63B shares outstanding.

As of September 30, 2023, CuraScientific Corp. trades at a trailing price-to-earnings ratio of 0.01. The price-to-sales ratio is 0.42, and the price-to-book ratio stands at -0.14.

These figures are as of September 30, 2023. The EV/Sales ratio of 6.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.11M versus a market cap of 3.42M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2023, CuraScientific Corp. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -2.96, indicating conservative leverage, while an interest coverage ratio of -20.39 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) stands at 2,028.95, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -75.28, pointing to unprofitable operations over the period. The company generates approximately 335,825.50 in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 11.63 indicates how many times CuraScientific Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2023, CuraScientific Corp. generated 671,651.00 in revenue and converted that into 33.68M in net income, yielding earnings per share of 0.15. EBITDA reached -4.16M, while operating income came in at -2.91M.

As of September 30, 2023, CuraScientific Corp. holds 40,911.00 in cash and equivalents against 733,931.00 in total debt, resulting in a net debt position of 577,124.00. Total book value stands at -24.78M, with working capital of -24.98M providing operational flexibility.

CuraScientific Corp. produced -304,302.00 in operating cash flow over the twelve months ended September 30, 2023. After subtracting -97,686.00 in capital expenditures, free cash flow totaled -401,988.00 - equivalent to 0.00 per share.

Over the twelve months ended September 30, 2023, CuraScientific Corp. posted a gross margin of 49.34, reflecting its pricing power and cost economics. The operating margin of -432.79 and net profit margin of 5,015.07 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2023. Free cash flow yield is negative at -135.54: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.71, meaning CuraScientific Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

CuraScientific Corp.'s most recent stock split took place on April 24, 2023 with a 500:1 split ratio.

As of September 30, 2023, CuraScientific Corp. has an Altman Z-Score of -10.64, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.